Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease.

Brain communications·2026
Same author

Biomarkers in Alzheimer's disease clinical trials: 2025.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials.

The journal of prevention of Alzheimer's disease·2025
Same author

Harnessing combination therapy: Current treatments, recent advancements, and future directions in Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2025
Same author

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.

Alzheimer's & dementia (New York, N. Y.)·2024
Same author

Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia.

Journal of the American Geriatrics Society·2024

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Howard M Fillit1

  • 1Alzheimer's Drug Discovery Foundation, New York, NY, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Developing blood tests for tau pathology is crucial for Alzheimer's disease (AD) care. These tests will enable precise patient stratification and personalized treatments, improving outcomes beyond current amyloid-based diagnostics.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Precision Medicine

Background:

  • Stratifying Alzheimer's disease (AD) patients by tau burden is vital for research and clinical care.
  • Tau pathology strongly correlates with patient outcomes, as shown in studies like LEQ and DONA.
  • Current blood biomarkers primarily detect amyloid pathology, limiting comprehensive AD assessment.

Purpose of the Study:

  • To highlight the need for cost-effective, non-invasive blood tests for tau pathology detection independent of amyloid.
  • To emphasize the importance of tau biomarkers for predicting disease progression and guiding therapeutic interventions.
  • To advocate for patient stratification using both amyloid and tau biomarkers for personalized AD care.

Main Methods:

  • Review of clinical trial data (LEQ, DONA) correlating tau pathology with patient outcomes.
  • Analysis of existing imaging and cerebrospinal fluid (CSF) studies on tau's role in AD.
  • Discussion of current limitations of blood-based amyloid biomarkers (e.g., plasma amyloid-β ratios).

Main Results:

  • Tau pathology is a critical predictor of patient outcomes and disease progression in Alzheimer's disease.
  • Existing blood tests predominantly focus on amyloid, failing to capture tau's contribution.
  • Development of independent tau blood tests is essential for comprehensive AD assessment.

Conclusions:

  • Integrating tau biomarkers into clinical practice will enable precise patient stratification and personalized therapeutic strategies.
  • Tailoring treatments based on individual amyloid and tau profiles can optimize efficacy and slow disease progression.
  • The evolution of AD care hinges on developing advanced biomarkers, including tau, for precision medicine and next-generation therapies.